⚕ GalenOps field
←

SITE001-0349

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-04-23

AEs
9
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-04 (study day 5); relationship: Y

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-04 (study day 5); relationship: N

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-05 (study day 6); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 18); relationship: Y

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 18); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-18 (study day 19); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-19 (study day 20); relationship: N

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-27 (study day 28); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-01 (study day 33); relationship: not assessed

Data queries

No data queries.